Inclusion Criteria:
* Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
* Assigned sex at birth will determine sex-specific recruitment and PROs (male vs female) employed, when needed
* Resides in the United States
* Reports experiencing pain or burning in their upper abdomen at least once a week
* Reports experiencing mild to severe discomfort in their upper abdomen
* Reports no physical cause for their GI symptoms
* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Exclusion Criteria:
* Report being pregnant, trying to become pregnant, or breastfeeding
* Unable to provide a valid US shipping address and mobile phone number
* Reports current enrollment in another clinical trial
* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
* Unable to read and understand English at a 7th grade level
* Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk
* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. This may include:
* NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. This may include:
* Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, Proton Pump Inhibitors, or thyroid products
* Reports vomiting once per week or more due to GI discomfort
* Reports taking antibiotics within the month before starting the study
* Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk
* Medical history of upper GI surgery or other diagnosed significant disorders (inflammatory bowel disease, ulcerative colitis, coeliac disease, Crohn's disease)
* Lack of reliable daily access to the internet Biomarker collection note: participants residing in New York, New Jersey, or Rhode Island may enroll in the main study but are not eligible for the optional biospecimen collection.
